Cargando…

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of cholesterol-lowering medications that provide significant reductions in lipids but at a large cost relative to statins. With 2 such drugs now on the market, alirocumab and evolocumab, comparing the ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	McDonagh, Marian, Peterson, Kim, Holzhammer, Brittany, Fazio, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397903/ https://www.ncbi.nlm.nih.gov/pubmed/27231792 http://dx.doi.org/10.18553/jmcp.2016.22.6.641

Ejemplares similares

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
por: Choi, Hye Duck, et al.
Publicado: (2023)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
por: Choi, Joshua, et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia
por: Ge, Xiaoyue, et al.
Publicado: (2021)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
por: Huang, Hui-Chun, et al.
Publicado: (2022)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project
por: McDonagh, Marian S., et al.
Publicado: (2018)

The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
por: Izkhakov, Elena, et al.
Publicado: (2021)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review
por: Luthra, Gaurav, et al.
Publicado: (2022)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody
por: Hopkins, Paul N., et al.
Publicado: (2015)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
por: Silla, Alessia, et al.
Publicado: (2023)

No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
por: Colhoun, Helen M., et al.
Publicado: (2016)

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo: An Effect Blunted by Alirocumab
por: Villard, Elise F., et al.
Publicado: (2016)

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study
por: Banach, Maciej, et al.
Publicado: (2023)

Systematic review of published Phase 3 data on anti‐PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
por: Gouni‐Berthold, Ioanna, et al.
Publicado: (2016)

Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy
por: Beltran, Roman A., et al.
Publicado: (2022)

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab
por: Chemello, Kévin, et al.
Publicado: (2020)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat
por: Wang, Hong-Fei, et al.
Publicado: (2022)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
por: Warden, Bruce A., et al.
Publicado: (2020)

Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis
por: Liang, Di, et al.
Publicado: (2022)

Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review
por: McDonagh, Marian S., et al.
Publicado: (2018)

Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
por: Toth, Peter P., et al.
Publicado: (2017)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
por: Leucker, Thorsten M., et al.
Publicado: (2020)

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
por: Gibbs, John P., et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment
por: Gibbs, John P., et al.
Publicado: (2016)

Telehealth for Women’s Preventive Services for Reproductive Health and Intimate Partner Violence: a Comparative Effectiveness Review
por: Cantor, Amy G., et al.
Publicado: (2023)

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes
por: Ramanathan, Aarti, et al.
Publicado: (2016)

Application of the COM-B model to barriers and facilitators to chlamydia testing in general practice for young people and primary care practitioners: a systematic review
por: McDonagh, Lorraine K, et al.
Publicado: (2018)

Painful and recurring injection site reaction to alirocumab and evolocumab in a young woman with familial hypercholesterolemia and effective therapeutic alternative based on inclisiran: a case report
por: Allevi, Massimiliano, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q01299suvgs624vsc0mdrvlm5j